0

InvestorPresentation

MARCH

2017

Accelerating Biomedical Technologiesfrom Incubation to Monetization

QBIO

Forward Looking StatementsThis presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which arenot purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentionsregarding the future. These forward-looking statements generally can be identified by phrases such as Q BioMed, Inc. (“QBIO”) or itsmanagement "believes," "expects," "anticipates," "foresees," "forecasts," "estimates" or other words or phrases of similar importance.Such forward-looking statements include, among other things, the development, costs and results of new business opportunities.Actual results could differ from those project these forward-looking statements are made as of the date of this presentation, and weassume no obligation to update any forward-looking statements due to numerous factors. forward-looking statements, or to update thereasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs,plans, expectations and intentions contained in this presentation are reasonable, there can be no assurance that any such beliefs,plans, expectations or intentions will prove to be accurate. Investors should review all of the information set forth herein, and shouldalso understand the risk factors and the inherent uncertainties associated with new business opportunities and development stage.Any use of this information for any purpose other than in connection with the consideration of an investment in Q BioMed, Inccompanies. (“QBIO”) may subject the user to criminal and civil liability.

This presentation does not constitute an offer to sell any securities or the solicitation of an offer to sell any securities by Q BioMed Inc.

Biotech Growth &The Problem It Created QBioMed Solves It by Accessing Undiscovered

Biomedical Technologies for Investment

Pharma sales continue on a five-year growth track

and is expected long term.

An aging population provides consistent demand

and high growth rates.

Demand for affordable drugs remains inelastic.

International market growth creates a positive

Global Market Growth Estimate

The Biotech & The Life Science Sectors

0

200

400

600

800

1000

1200

2010 2011 2012 2013 2014 2015

Sales $M 60+ Population

Pharma Sales Linked to 60+ Population

However, the reality for many is approximately 8 out of 10 biomedical ideas

are under-recognized and under-capitalized.

Only very few have access to capital leaving

viable ideas unfunded and neglected.

Sources: UNDESA Population and Pharmafile

0

50

100

150

200

250

300

350

400450

500

2015 2016 2017 2018 2019

USD $B

Global Biotech Market Estimate

Sources: UNDESA Population and Pharmafile

p. 4

of biomedical start ups lack capital and resources to transition from incubation to development and beyond.

Reasons

Too small Unrealistic goals Unproven IP/ formulation

Missed milestones Not ready to go public Previous financing

Cannot attract / retain talent Not attracting partnerships

80

The Result Billions of dollars in market value remain locked in academia, early-

stage IP, unfocused management, challenging capital structures and failed IPOs. Investors cannot access them. They live in limbo or stuck in ‘dead money’

investments.

The Problem%

QBioMed Solves the Problem by

availing capital to develop biomedical technologies while

also providing investors access to participate in

our assets' growth and value.

p. 5

Our vision is to create a pipeline of innovative biomedical assets in various

stages of development in multiple therapeutic areas. Our strategy will minimize risk, share success and accelerate our assets' technologies to monetization.

Asset Search and Due Di l igence Ongoing Since Incept ion

Management Team

GRAH 1Denis Corin William Rosenstadt David Laskow-Pooley Ari Jatwes

Chief Executive Officer

Chairman of the Board

General Counsel

Director

VP Product Development

Director

Analyst

Director

Advisory Board

Dr. Geert Cauwenberg

Dermatology, Wound, Infectious

Diseases, Women’s Health

Dr. Helga Grupe

Oncology

Dr. Jose de Chastonay

Contract Services

Dr. Scott P Bruder

Medical Devices, Orthopedics

and Regenerative Medicine

Andy Watson

Diagnostics, Companions,

Genomics, Life Science Tools

John Erb

Medical Device

Cardio Vascular

Mary Jan Rafii

Ophthalmology

Dr. Susan Quaggin

CSO, Manin Resarch

George Nikopoulos

CEO, Mannin Research

Rosanne Satz

CEO, BioNucleonics,

Dr. Stanley Satz

Chairman, BioNucleonics

Jean-Jaques

Mondoloni

Advisor Wombat Capital

Our Milestones

August Established

Management Team

June

Initiated new

business model

October MAN-01 Exclusive

License Option

February SR89 Exclusive

License Option LOI

April MAN-01

Molecule Opt.

September Closes SR89

License Option

November

$4 M

Financing

September Engages Wombat

Capital as Scientific

Advisor

Planned

1Q 2017

initial Sr89

production

2015 2016 2017

p. 7

We unlock capital through US public markets to fund the development of our assets.

We make liquid investments in high-value assets that can produce exponential returns.

We diversifiy risk over several therapies in various stages of development and deploy performance-

based capital only.

We accelerate our assets' development with our management and advisory teams'

expertise, experience, and industry relationships.

How We Accelerate Biomedical Technology Development

Our ownership of an asset and our ROI steadily increase as assets hit milestones

and cross value-creating events during development lifecycles.

Our Business Model

INVESTCapital attached to goals

ACCELERATEIncrease investment and ownership

MONETIZEOperate, partner, license, IPO or sell

Preliminary scientific and commercial criteria review. Determining management's expectations and flexibility moves the asset to the next step.

Due diligence is combined with a validation of management's development and capital requirements.

Performance-based capital is deployed to meet specific and mutually-agreed goals in each stage.

Additional resources are infused to move the asset through development stages and to a value-creating inflection point.

Assets can be sold, licensed, joint-ventured or operated as cash flow positive product lines. QBIO's goal is to maximize value for its shareholders.

IDENTIFYCriteria match and fit

ANALYZEAsset and development plan

The Importance of an Asset's Development Plan

Development plans provide QBio a tool to assess management's

work to date and an insight into an asset's biomedical

technology and value.

The plan should have clearly defined milestones and quantify

capital needed to accelerate development.

QBIO's Team and Advisors can pinpoint their resources

to help transition a plan through development

to monetization.

Managing to milestones mitigates investment risk. QBio's capital

is released only when milestones are met.

A Requirement to Access QBio Capital

Drug Candidate Preclinical Phase 1 Phases 1b/2a Phase 3 Approval

A Growing Pipeline Mitigates Risk and Drives Shareholder Value

In YEARS 1&2 we are focused on licensing and acquiring assets, some with near term (6-12 months) REVENUE or value-creating opportunities.

In YEARS 2&3 we will look to grow the pipeline and monetize investments through partnerships, JV, IPO and sales revenue growth.

ASSET 1SR-89 Radiopharmaceutical

ASSET 2MAN – 01 Topical Eye Drops

TARGET ASSET 4

TARGET ASSET 5 Protocol Design for Ph4

ASSET 3UTTROCIDE-B Chemotherapy

TARGET ASSET 6 IND Preparation for Ph2/3

p. 11

Drug Candidate 505(b)2 Preclinical Phase 1 Phases 2/3 Phase 4 Approval

Our Current Portfolio of High-Value Assets

Strontium Chloride Sr89Injection, USP

FDA-Approved, Commercialization Planning and

Accelerating Development of Additional

Large-Market Therapies

UTTROCIDE-B

Pharmaceutical: Generic SR-89

Radiopharmaceutical

Condition: Bone Cancer Therapy

and Pain Management

Addressable

Market:

~110,000 yearly

diagnoses from

breast and prostate

cancers

Technology BioNucleonics

Stage: - Approved

Commercializing

Asset 1

Strontium Chloride Sr89Injection, USP

BONE METASTESES from Prostate and Breast Cancer

▪ Pain is the most common sign of bone cancer, and may

become more noticeable as the tumor grows.

▪ Bone pain can cause a dull or deep ache in a bone

or bone region (e.g., back, pelvis, legs, ribs, arms).

▪ Treatment options include:Pain Medications - OpioidsOrthopedic ProceduresRadiation TherapyRadiopharmaceuticals

▪ Sr89 is NON-NARCOTIC and can mitigate opioid

use and abuse

Pain Management

▪ 450,000* new breast and prostate cases are

recorded each year

▪ 1 in 3 people will develop bone metastases from the

spread of breast and prostate cancer

*Source: American Cancer Society, 2016p. 14

Market Potential for Bone Cancer Pain Palliation is

Estimated at $60-$80 Million

How it worksDrug targets bone-cancer afflicted areas providing direct radiation to destroy active cancer cells and relieve symptoms.

Effective In 70% of patients, usually within two weeks and can last six months.

▪ Indicated to relieve bone pain from skeletal metastases from breast and prostate cancers

▪ Can be used with opioid based drugs and cancer

therapeutics

▪ Studies demonstrated a prolonged progression-free result and overall survival with acceptable

toxicity

p. 15

Strontium Chloride Sr89Injection, USP

Non OpioidPain Medication

Pharmaceutical: MAN-01 Topical

Drops

Condition: Glaucoma

Addressable

Market:

60 million patients

worldwide

Technology

Stage: Exiting Preclinical

MAN-01

Asset 2

60 million patients worldwide

8 million with bilateral blindness

Typically no early warning signs

Therapy only slows progression

GLAUCOMAA Devastating Condition with No Cure

Vision with Glaucoma

Current Standards of Care

Medical (Pharmaceuticals)No new glaucoma pharmaceutical in 20 years (1996)

Laser Surgery (Out-patient)Requires two procedures and use of pharmaceuticals

Traditional Surgery (In-patient)Requires two procedures and use of pharmaceuticals

Painful, costly, and invasive Normal vision

p. 17

60.5

79.6

0

10

20

30

40

50

60

70

80

90

2010 2020

Drug (Company) Target/MOA Stage

BOL-303259 (Bausch +

Lomb) NO-donating latanoprost Phase 3

K115 (Kowa) ROCK Inhibitor Phase 3

DE-117 (Santen) EP2 agonist Phase 2a

ONO-9054 (Ono) FP/EP3 agonist Phase 1

AMA0076 (Amakem) ROCK Inhibitor Phase 2a

LX7101 (Lexicon) LIMK2 inhibitor Phase 1/2

SYL040012 (Sylentis) RNAi beta blocker Phase 2

AR-13324 (Aerie) ROCK/NET Inhibitor Phase 3

▪ First in class drug for Intraocular Eye PressureNo new drugs in "IOP" for 20 years

▪ Only drug targeting the critical ‘Schlemms’ Canal

The Schlemms Canal is responsible for 70%-90% of fluid

drainage in the eye

▪ Testing results shows normalizing IOP

▪ Primary indication for Adult Open Angle Glaucoma

Additional indications may include:

- Age Related Macular Degeneration (AMD)

- Cystic Kidney Disease

▪ Mannin Research accepted into Johnson & Johnson Innovation, JLABS @ Toronto

Partnership to develop a novel eye-drop to treat Primary Open-

Angle Glaucoma utilizing the Tie2 Mechanism of Action

Treatment Comparative AnalysisNone of the follow address the Schlemms Canal

Source: W.H.O. 2010

Glaucoma Cases Expected to Increase 30% by 2020(millions of cases)

▲3

0%

In

cre

as

e in

Cas

es

Glaucoma Drug

Public Market Comp Aerie Pharmaceuticals - AERI $1.5 b MCAP

MAN-01

p. 18

Pharmaceutical: Uttrocide-B

Condition: Liver Cancer

Addressable

Market:

700,0000 diagnoses

per year

Technology: Chemotherapy

Stage: Exiting Preclinical

UTTROCIDE-B

Asset 3

Estimated 39,230 adults in the

United States will be diagnosed every year

Short 1-year survival rate

More than 700,000 people

worldwide are diagnosed each year

LIVER CANCER10th Most Common Cancer

Current Standards of Care

Surgical Hepatectomy or Liver Transplantation

Thermal AblationRadiofrequency ablation (RFA) and microwave therapy

Percutaneous ethanol injectionAlcohol is injected directly into the liver tumor

RadiationHigh-energy x-rays or other particles destroy cancer cells

Drug Treatment tryosine kinase inhibitor antineoplastic agent, Nexavar™

p. 20

500

5800

0

1000

2000

3000

4000

5000

6000

Uttrocide-B Sorafenib

Sorafenib Tosylate (Nexavar™) is the only FDA approved drug for the treatment of liver cancer

P Uttroside-B appears to affect phosphorylated JNK (pro survival signaling) and capcase activity (apoptosis in liver cancer)

A natural compound

Fractionated Saponin derived from S. nigrum

Small molecule

Steriod Glycoside

Uttroside B increases the cytotoxicity of a variety of liver cancer cell types

Up to 10x more potent than Sorafenib in

pre clinical studies

Cytotoxicity specific to cancerous liver cells

Provisional patent filed

Chemotherapy

OMRF’S SolutionA compound that increases cytotoxicity in liver cancer cells by increased

apoptosis and decreased pro survival signaling

UTTROCIDE-BIN VITROIC-50 of Sorafenib is 5.8 uM in Hep G2 while Uttrocide-B is 500

IN VIVOHepG2 Injected Into Mice Then Treated with 10mg of Uttrocide-B for One Month

0

20

40

60

80

100

120

140

160

Week 1 Week 2 Week 3 Week 4

Control Uttrocide B p. 21

0

100,000

200,000

300,000

400,000

500,000

600,000

$0.00

$1.00

$2.00

$3.00

$4.00

$5.00

$6.00

$7.00

$8.00

12/5/2016 1/4/2017 2/3/2017

News Flow

Q Biomed Joins with Oklahoma Medical

Research Foundation and Rajiv Gandhi

Centre for Biotechnology to Develop Liver

Cancer Chemotherapeutic

Q BioMed Inc. Announces Mannin Research

Accepted Into Johnson & Johnson Innovation,

JLABS @ Toronto

Q BioMed Inc. Announces Entry Into

Definitive Funding Agreement for up to

$4,000,000

Q BioMed Inc. Technology Partner Mannin

Research Inc. to Participate in a Webcast on

Innovating for Ophthalmic Diseases

Q BioMed Drug Development Partner to

Attend EANM 2016 in Barcelona, Spain

October 15-19 2016

Q BioMed Partner Mannin Research

Executives Attending

OIS@AAO 2016 & AAO

QBIO

3-Month Trading HistoryAs of March 1, 2017

Shares Outstanding

Warrants Data as of 11.30.16

9,200,000

1 MMarket Cap ~$40 M

Inside Ownership 35% Avg. Volume 125,421

Float 5,775,000 Yearend November 30

PR

ICE

VO

LU

ME

Recent Conferences

January 2017

Biotech Showcase, San Francisco

$3.95

p. 22

Low Float ● Tightly Held ● OwnershipAttractive entry level valuation

Current assets and acquisitions value

Revenue in 1H17

Launch and commercialize FDA-Approved SR89 Revenue generation expected in 1H17

Accelerate MAN-01 Asset DevelopmentMolecule optimization

Up list to National exchange in 1H 2017

Complete pre-clinical and Prepare IND for Uttrocide-B in Liver Cancer

Add one or two additional asset licenses in 2017

What to Expect From Us

1

2

3

4

QBIO

p. 23

5

Corporate501 Madison AvenueNew York, NY 10222

USA

+1 (888) 357-2435

Executive & Investors

Denis Corin, CEO

dcorin@qbiomed.com

Accelerating Biomedical Technologies

from Incubation to Monetization

QBIO